CAMBRIDGE, Mass. – Beam Therapeutics Inc . (NASDAQ:BEAM), a $2.1 billion market cap pioneer in the field of precision genetic medicines through base editing, is set to present new data from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback